The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Open accessAbstract
Aggregation of biotherapeutics has the potential to induce an immunogenic response. Here, we show that aggregated therapeutic antibodies, previously generated and determined to contain a variety of attributes (Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., and Narhi, L. O. (2011) J. Biol. Chem. 286, 25118-25133), can enhance the in vitro innate immune response of a population of naive human peripheral blood mononuclear cells. This response depended on the aggregate type, inherent immunogenicity of the monomer, and donor responsiveness, and required a high number of particles, well above that detected in marketed drug products, at least in this in vitro system. We propose a cytokine signature as a potential biomarker of the in vitro peripheral blood mononuclear cell response to aggregates. The cytokines include IL-1β, IL-6, IL-10, MCP-1, MIP-1α, MIP-1β, MMP-2, and TNF-α. IL-6 and IL-10 might have an immunosuppressive effect on the long term immune response. Aggregates made by stirring induced the highest response compared with aggregates made by other methods. Particle size in the 2-10 μm range and the retention of some folded structure were associated with an increased response. The mechanism of aggregate activation at the innate phase was found to occur through specific cell surface receptors (the toll-like receptors TLR-2 and TLR-4, FcγRs, and the complement system). The innate signal was shown to progress to an adaptive T-cell response characterized by T-cell proliferation and secretion of T-cell cytokines. Investigating the ability of aggregates to induce cytokine signatures as biomarkers of immune responses is essential for determining their risk of immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors
Brightbill, H. D., Libraty, D. H., Krutzik, S. R., Yang, R.-B., Belisle, J. T., Bleharski, J. R., Maitland, M., Norgard, M. V., Plevy, S. E., Smale, S. T., et al. (1999) · Science · doi:10.1126/science.285.5428.732 · Cited by 1,661
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., & Plebanski, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3148 · Cited by 664
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators
Tilg, H., Dinarello, C. A., & Mier, J. W. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01103-1 · Cited by 633
Pathogen recognition and development of particulate vaccines: Does size matter?
Xiang, S. D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P. L., & Plebanski, M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.016 · Cited by 602
Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Russell Middaugh, C., Winter, G., Fan, Y.-X., Kirshner, S., Verthelyi, D., Kozlowski, S., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21530 · Cited by 595
Cited by
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 529
Self-citationTherapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
Physicochemical Stability of Monoclonal Antibodies: A Review
Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A., & Sautou, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.009 · Cited by 429
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Pickens, C. J., Johnson, S. N., Pressnall, M. M., Leon, M. A., & Berkland, C. J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00633 · Cited by 285
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Self-citationThe evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“In this article the author has clearly shown that presence of large number of particles in therapeutic mAb formulation to induce immunogenicity through innate immune response, which may further progress through T-cell response [85].”
BackgroundHuman Monoclonal Antibodies: The Benefits of Humanization
Waldmann, H. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8958-4_1 · Cited by 80
Krayukhina, E., Yokoyama, M., Hayashihara, K. K., Maruno, T., Noda, M., Watanabe, H., Uchihashi, T., & Uchiyama, S. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.02.002 · Cited by 70
Chisholm, C. F., Nguyen, B. H., Soucie, K. R., Torres, R. M., Carpenter, J. F., & Randolph, T. W. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24573 · Cited by 55
Uchino, T., Miyazaki, Y., Yamazaki, T., & Kagawa, Y. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12765 · Cited by 49
In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice
Filipe, V., Que, I., Carpenter, J. F., Löwik, C., & Jiskoot, W. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1154-9 · Cited by 39
Chisholm, C. F., Soucie, K. R., Song, J. S., Strauch, P., Torres, R. M., Carpenter, J. F., Ragheb, J. A., & Randolph, T. W. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.02.008 · Cited by 31
Metadata
- Authors
- Joubert, M. K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M. P., Goletz, T. J., Kerwin, B. A., Chirmule, N., Narhi, L. O., & Jawa, V.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 287
- Issue
- 30
- Pages
- 25266-25279
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2048087821
- Cited by
- 268
- References
- 63
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.